BillionToOne is a precision diagnostics company developing advanced genetic testing solutions to detect and measure disease. BillionToOne has pioneered a DNA molecular counter that dramatically increases the resolution of cell-free DNA diagnostics—by over 1,000-fold compared to traditional methods. This breakthrough has enabled significant advancements in both prenatal screening and oncology liquid biopsy.
The Technology That Enabled BillionToOne
BillionToOne’s core innovation is its proprietary molecular counting technology, which allows highly precise measurement of DNA fragments in a blood sample. This increased sensitivity unlocks transformative possibilities for non-invasive testing. Their flagship product, the UNITY Screen, is a non-invasive prenatal test (NIPT) that uniquely screens for both fetal aneuploidies (like Down syndrome) and recessive genetic conditions—all from a single maternal blood draw. This sets UNITY apart from most NIPTs, which typically only screen for chromosomal abnormalities.
Beyond prenatal testing, BillionToOne is applying its technology to develop liquid biopsy tests for oncology. These next-generation tests aim to detect and monitor cancer using simple blood samples, potentially transforming cancer care through earlier detection and more precise monitoring.
Who Uses BillionToOne?
BillionToOne serves healthcare providers, genetic counselors, and clinical laboratories seeking more accurate, comprehensive non-invasive genetic testing for their patients. Its UNITY Screen is being adopted by an increasing number of clinics and health systems, with published studies supporting its accuracy and clinical value. The company’s technology is particularly valuable for:
- Obstetricians and maternal-fetal medicine specialists seeking advanced prenatal screening tools
- Oncology teams interested in cutting-edge liquid biopsy solutions
- Clinical laboratories aiming to offer next-generation genetic testing services
Who Are BillionToOne’s Competitors?
BillionToOne operates in the competitive genetic diagnostics and non-invasive prenatal testing (NIPT) space. Notable competitors include:
- Natera: Offers the Panorama NIPT, a blood-based prenatal screening test for chromosomal conditions.
- Other industry players (not listed directly in the provided data) include companies like Illumina, Invitae, and Myriad Genetics, which also offer genetic testing and diagnostic solutions. BillionToOne differentiates itself with its unique molecular counting approach and ability to assess both chromosomal and recessive risk in a single NIPT.
Use PromptLoop to Uncover Company Data
Looking for more company insights like this? PromptLoop helps you go deeper, providing unique data points and analysis on companies like BillionToOne and many others. Automate your research and find the information that matters most. Discover how PromptLoop can accelerate your market intelligence. Get A Free Demo to learn more.